Colorectal cancer (CRC) screening, the decade's most promising cancer-related public health development, is evolving. Faecal immunochemical tests (FIT) will be the primary population-based CRC screening biomarker for the next 10–15 years. Will the international community exploit the full potential of FIT and other CRC risk indicators to enable a revolution in the effectiveness of screening?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kapidzic, A. et al. Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am. J. Gastroenterol. Gut 109, 1257–1264 (2014).
Hol, L. et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59, 62–68 (2010).
van Roon, A. H. C. et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut 62, 409–415 (2013).
Lo, S. H. et al. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme. Gut http://dx.doi.org/10.1136/gutjnl-2013-306144.
Gupta, S. et al. Challenges and possible solutions to colorectal cancer screening for the underserved. J. Natl Cancer Inst. 106, dju032 (2014).
Quintero, E. et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N. Engl. J. Med. 366, 697–706 (2012).
Steele, R. J. C. et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United European Gastroenterol. J. 1, 198–205 (2013).
Grazzini, G. et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br. J. Cancer 100, 259–265 (2009).
Terhaar sive Droste, J. S. et al. Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol. Biomarkers Prev. 20, 272–280 (2011).
Chen, L. S. et al. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet 12, 551–558 (2011).
Acknowledgements
S.P.H. acknowledges support from The NHS Bowel Cancer Screening Programme, Royal Surrey County Hospital NHS Foundation Trust and University of Surrey.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Halloran, S. Colorectal cancer screening—insights and challenges. Nat Rev Gastroenterol Hepatol 11, 586–587 (2014). https://doi.org/10.1038/nrgastro.2014.150
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.150
